Apogee Therapeutics, Inc. (NASDAQ:APGE) Director Mark C. Mckenna Buys 20,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) Director Mark C. Mckenna purchased 20,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $49.54 per share, for a total transaction of $990,800.00. Following the completion of the acquisition, the director now directly owns 20,000 shares in the company, valued at approximately $990,800. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Apogee Therapeutics Trading Up 0.4 %

NASDAQ:APGE opened at $44.50 on Monday. Apogee Therapeutics, Inc. has a twelve month low of $20.78 and a twelve month high of $72.29. The company has a market cap of $2.00 billion, a PE ratio of -18.39 and a beta of 2.30. The company’s 50 day moving average is $51.43 and its two-hundred day moving average is $48.30.

Institutional Investors Weigh In On Apogee Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in Apogee Therapeutics by 11.2% in the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after acquiring an additional 82,978 shares during the last quarter. Barclays PLC increased its holdings in shares of Apogee Therapeutics by 369.2% in the third quarter. Barclays PLC now owns 365,046 shares of the company’s stock valued at $21,443,000 after purchasing an additional 287,243 shares during the period. Wellington Management Group LLP increased its holdings in shares of Apogee Therapeutics by 35.7% in the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after purchasing an additional 1,267,451 shares during the period. Wexford Capital LP purchased a new position in shares of Apogee Therapeutics in the third quarter worth about $230,000. Finally, Point72 DIFC Ltd lifted its holdings in shares of Apogee Therapeutics by 14.5% during the third quarter. Point72 DIFC Ltd now owns 19,207 shares of the company’s stock worth $1,128,000 after purchasing an additional 2,428 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on APGE. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday. Wedbush lifted their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $83.88.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.